GlassScriptPhysician profile
David L Atkins
NPI 1053632315
$619.06
in general payments reported to CMS, 2019-2025
14 companies · $21.45 in 2025
The $21.45 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $32.20 · 2021: $11.89 · 2022: $40.43 · 2023: $199 · 2024: $151 · 2025: $21.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $164.15 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $97.98 | 2019-2020 | |
| Amgen INC. | $70.84 | 2019-2024 | Evenity, Prolia |
| Mylan Specialty L.P. | $70.46 | 2022-2024 | Yupelri |
| Dexcom, INC. | $32.41 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.05 | 2019 | |
| Insulet Corporation | $28.85 | 2024 | Omnipod |
| Lilly USA, LLC | $25.30 | 2021-2024 | |
| Viatris Specialty LLC | $21.45 | 2025 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $19.94 | 2024 | Rexulti |
| Smith+Nephew, INC. | $17.11 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.76 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.61 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $12.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Atkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.